《復牌表現》泰凌(01011.HK)彈13%曾越百天線 擬悉售附屬泰凌醫藥國際料獲利3,410萬
泰凌醫藥(01011.HK)擬向北京康辰(603590.SH)旗下之康辰生物出售附屬泰凌醫藥國際全部股權,預期就可能出售事項實現估計收益總額約3,410萬元,款項將用作還債。
該股今早復牌曾一舉升破20天、10天、50天及百天線(0.172元/0.179元/0.185元/0.194元),急彈32%高見0.22元遇阻,現造0.189元,反彈13%,成交增至3,127萬股,涉資620萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.